MEF-2D Antibody (9): sc-136196
- MEF-2D Antibody (9) is a mouse monoclonal IgG1, cited in 2 publications, provided at 50 µg/0.5 ml
- raised against amino acids 346-511 of MEF-2D of mouse origin
- recommended for detection of MEF-2D of mouse, rat, human and canine origin by WB, IP and IF; not recommended for IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for MEF-2D Antibody (9). This work is in progress.
MEF-2D Antibody (9) is a mouse monoclonal IgG1 antibody that detects myocyte enhancer factor-2D (MEF-2D) in mouse, rat, human, and canine samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). MEF-2D plays a crucial role in the regulation of gene expression during muscle cell differentiation, as MEF-2D is a member of the MEF-2 family of transcription factors that bind to specific DNA sequences in promoter regions of target genes. MEF-2D (9) antibody recognizes a protein primarily located in the nucleus, where MEF-2D interacts with various corepressors and co-activators to modulate muscle-specific gene transcription, thereby influencing muscle development and function. MEF-2D′s ability to form homo- and heterodimers with other MEF-2 family members allows for a complex regulatory network essential for proper muscle differentiation and function. Understanding MEF-2D dynamics and interactions is vital, as dysregulation can lead to muscle-related diseases and developmental disorders. Anti-MEF-2D antibody (9) serves as an invaluable tool for researchers studying muscle biology and transcriptional regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MEF-2D Antibody (9) References:
- Activation of the beta myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway. | Meissner, JD., et al. 2007. J Cell Physiol. 211: 138-48. PMID: 17111365
- Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. | Gu, Z., et al. 2016. Nat Commun. 7: 13331. PMID: 27824051
- Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. | Xiang, J., et al. 2020. Gastroenterology. 158: 664-678.e24. PMID: 31678303
- DYRK1A phosphorylates MEF2D and decreases its transcriptional activity. | Wang, P., et al. 2021. J Cell Mol Med. 25: 6082-93. PMID: 34109727
- Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion. | Zhang, M., et al. 2022. Blood. 140: 1390-1407. PMID: 35544603
- Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis. | Wang, L., et al. 2023. Biomed Pharmacother. 165: 115255. PMID: 37549462
- A Ubiquitin-Dependent Switch on MEF2D Senses Pro-Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer. | Xiang, J., et al. 2023. Adv Sci (Weinh). 10: e2305550. PMID: 37828611
- MEF2D facilitates liver metastasis of gastric cancer cells through directly inducing H1X under IL-13 stimulation. | Zhang, Y., et al. 2024. Cancer Lett. 591: 216878. PMID: 38609001
- Mef2d potentiates type-2 immune responses and allergic lung inflammation. | Szeto, ACH., et al. 2024. Science. 384: eadl0370. PMID: 38935708
- The Molecular and Biological Function of MEF2D in Leukemia. | Zhang, P. and Lu, R. 2024. Adv Exp Med Biol. 1459: 379-403. PMID: 39017853
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MEF-2D Antibody (9) | sc-136196 | 50 µg/0.5 ml | $322.00 |